Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune stock logo
ACIU
AC Immune
$2.08
-1.4%
$1.85
$1.43
$4.26
$208.85M1.62143,005 shs17,998 shs
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$9.67
-1.0%
$9.26
$6.38
$17.30
$940.40M1.421.22 million shs58,248 shs
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$0.00
$0.00
$1.59
$1K1.535.34 million shsN/A
Verastem, Inc. stock logo
VSTM
Verastem
$4.68
-1.2%
$6.16
$2.10
$9.10
$258.54M0.711.28 million shs151,770 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$2.93
-1.2%
$2.87
$2.50
$8.32
$89.85M0.9867,779 shs2,205 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune stock logo
ACIU
AC Immune
+1.44%+2.43%-4.09%+35.26%-38.84%
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
+2.30%+9.47%-4.50%+27.21%-39.39%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
0.00%0.00%0.00%0.00%-99.99%
Verastem, Inc. stock logo
VSTM
Verastem
-1.46%-0.42%-22.55%+2.16%+73.63%
XBiotech Inc. stock logo
XBIT
XBiotech
-3.27%-6.48%+1.72%-9.76%-52.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AC Immune stock logo
ACIU
AC Immune
2.9585 of 5 stars
3.53.00.00.03.70.80.6
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
2.7154 of 5 stars
3.53.00.00.01.91.70.6
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
2.6301 of 5 stars
3.53.00.00.00.82.50.6
XBiotech Inc. stock logo
XBIT
XBiotech
0.4986 of 5 stars
0.00.00.00.02.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AC Immune stock logo
ACIU
AC Immune
3.00
Buy$12.00476.92% Upside
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
3.00
Buy$18.1787.83% Upside
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
0.00
N/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
3.00
Buy$13.38185.61% Upside
XBiotech Inc. stock logo
XBIT
XBiotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MTEM, ACIU, VSTM, XBIT, and AVDL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Verastem, Inc. stock logo
VSTM
Verastem
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.00
5/9/2025
Verastem, Inc. stock logo
VSTM
Verastem
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $14.00
5/8/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
5/1/2025
AC Immune stock logo
ACIU
AC Immune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AC Immune stock logo
ACIU
AC Immune
$31.02M6.73N/AN/A$1.29 per share1.61
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$194.45M4.81N/AN/A$0.77 per share12.56
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$23.48M0.00N/AN/A$0.78 per share0.00
Verastem, Inc. stock logo
VSTM
Verastem
$10M25.73N/AN/A($0.65) per share-7.20
XBiotech Inc. stock logo
XBIT
XBiotech
$4.01M22.24N/AN/A$5.98 per share0.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AC Immune stock logo
ACIU
AC Immune
-$57.83M-$0.58N/AN/AN/A-177.79%-44.60%-22.25%8/5/2025 (Estimated)
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$48.83M-$0.27N/A161.20N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/A
Verastem, Inc. stock logo
VSTM
Verastem
-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)
XBiotech Inc. stock logo
XBIT
XBiotech
-$38.53M-$1.29N/AN/AN/A-21.14%-19.55%8/11/2025 (Estimated)

Latest MTEM, ACIU, VSTM, XBIT, and AVDL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
AC Immune stock logo
ACIU
AC Immune
-$0.18N/AN/AN/A$1.98 millionN/A
5/14/2025Q1 2025
XBiotech Inc. stock logo
XBIT
XBiotech
N/A-$0.36N/A-$0.36N/AN/A
5/13/2025Q1 2025
Verastem, Inc. stock logo
VSTM
Verastem
-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A
5/7/2025Q1 2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million
4/30/2025Q1 2025
AC Immune stock logo
ACIU
AC Immune
-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AC Immune stock logo
ACIU
AC Immune
N/AN/AN/AN/AN/A
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AC Immune stock logo
ACIU
AC Immune
N/A
1.53
1.53
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/A
2.73
2.33
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/A
1.56
1.56
Verastem, Inc. stock logo
VSTM
Verastem
N/A
3.50
3.50
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
29.15
29.15

Institutional Ownership

CompanyInstitutional Ownership
AC Immune stock logo
ACIU
AC Immune
51.36%
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
69.19%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
95.47%
Verastem, Inc. stock logo
VSTM
Verastem
88.37%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%

Insider Ownership

CompanyInsider Ownership
AC Immune stock logo
ACIU
AC Immune
4.60%
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
5.20%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
13.90%
Verastem, Inc. stock logo
VSTM
Verastem
2.10%
XBiotech Inc. stock logo
XBIT
XBiotech
33.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
AC Immune stock logo
ACIU
AC Immune
140100.41 million95.79 millionOptionable
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
7096.74 million91.71 millionOptionable
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
2606.58 million5.67 millionNo Data
Verastem, Inc. stock logo
VSTM
Verastem
5054.95 million53.80 millionOptionable
XBiotech Inc. stock logo
XBIT
XBiotech
10030.49 million20.40 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AC Immune stock logo

AC Immune NASDAQ:ACIU

$2.08 -0.03 (-1.42%)
As of 10:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Avadel Pharmaceuticals stock logo

Avadel Pharmaceuticals NASDAQ:AVDL

$9.67 -0.10 (-1.00%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Molecular Templates stock logo

Molecular Templates NASDAQ:MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Verastem stock logo

Verastem NASDAQ:VSTM

$4.68 -0.06 (-1.20%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$2.92 -0.04 (-1.18%)
As of 10:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.